Wealth Alliance LLC Has $4.87 Million Stock Position in Johnson & Johnson $JNJ

Wealth Alliance LLC lifted its holdings in Johnson & Johnson (NYSE:JNJ) by 9.0% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 26,286 shares of the company’s stock after purchasing an additional 2,161 shares during the period. Wealth Alliance LLC’s holdings in Johnson & Johnson were worth $4,874,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of the business. Abich Financial Wealth Management LLC bought a new position in shares of Johnson & Johnson in the 3rd quarter valued at approximately $26,000. Clayton Financial Group LLC bought a new stake in Johnson & Johnson during the third quarter worth approximately $28,000. Evolution Wealth Management Inc. bought a new position in shares of Johnson & Johnson in the second quarter valued at approximately $27,000. Semmax Financial Advisors Inc. lifted its stake in shares of Johnson & Johnson by 55.0% in the second quarter. Semmax Financial Advisors Inc. now owns 203 shares of the company’s stock worth $31,000 after buying an additional 72 shares during the last quarter. Finally, Compass Financial Services Inc boosted its holdings in shares of Johnson & Johnson by 707.1% during the 3rd quarter. Compass Financial Services Inc now owns 226 shares of the company’s stock worth $42,000 after buying an additional 198 shares during the period. 69.55% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on the stock. Rothschild & Co Redburn boosted their target price on shares of Johnson & Johnson from $180.00 to $210.00 and gave the stock a “neutral” rating in a research report on Thursday. Weiss Ratings reissued a “buy (b)” rating on shares of Johnson & Johnson in a research report on Wednesday, January 28th. Wolfe Research raised their target price on Johnson & Johnson from $225.00 to $240.00 and gave the company an “outperform” rating in a report on Monday, January 5th. Sanford C. Bernstein lifted their price target on Johnson & Johnson from $208.00 to $225.00 and gave the stock a “market perform” rating in a research report on Friday, January 23rd. Finally, Guggenheim boosted their target price on shares of Johnson & Johnson from $227.00 to $240.00 and gave the stock a “buy” rating in a research report on Friday, January 23rd. One analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and nine have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $232.70.

Johnson & Johnson Stock Performance

JNJ opened at $245.81 on Friday. The stock’s 50 day simple moving average is $220.45 and its 200-day simple moving average is $198.55. The company has a current ratio of 1.03, a quick ratio of 0.77 and a debt-to-equity ratio of 0.48. The stock has a market cap of $592.38 billion, a PE ratio of 22.28, a P/E/G ratio of 2.38 and a beta of 0.35. Johnson & Johnson has a 1 year low of $141.50 and a 1 year high of $246.96.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Saturday, January 31st. The company reported $2.46 earnings per share for the quarter. Johnson & Johnson had a net margin of 28.46% and a return on equity of 33.04%. The firm had revenue of $24.28 billion for the quarter. Sell-side analysts forecast that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Tuesday, February 24th will be paid a $1.30 dividend. This represents a $5.20 annualized dividend and a dividend yield of 2.1%. The ex-dividend date is Tuesday, February 24th. Johnson & Johnson’s payout ratio is currently 47.06%.

Insider Activity

In other news, EVP Vanessa Broadhurst sold 6,197 shares of the firm’s stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $243.39, for a total transaction of $1,508,287.83. Following the completion of the sale, the executive vice president owned 23,003 shares of the company’s stock, valued at approximately $5,598,700.17. This trade represents a 21.22% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP Timothy Schmid sold 22,623 shares of the firm’s stock in a transaction on Wednesday, February 18th. The shares were sold at an average price of $244.33, for a total value of $5,527,477.59. Following the sale, the executive vice president directly owned 26,769 shares of the company’s stock, valued at $6,540,469.77. This represents a 45.80% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 0.16% of the stock is currently owned by corporate insiders.

Trending Headlines about Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Company is preparing a potential sale of its orthopedics unit that could fetch about $20 billion — investors may view a sale as value‑unlocking and a catalyst for multiple expansion if executed. Johnson & Johnson explores $20 billion sale of an orthopedics unit, Bloomberg News reports
• Positive Sentiment: Announced a >$1 billion investment in a Pennsylvania cell‑therapy manufacturing facility — expands U.S. capacity for high‑value biologics/cell therapies and supports long‑term revenue pipeline potential. Johnson & Johnson Expands U.S. Footprint with more than $1 Billion Investment in Next Generation Cell Therapy Manufacturing Facility in Pennsylvania
• Positive Sentiment: Strong early oncology data: investigational RYBREVANT FASPRO plus immunotherapy showed a 56% overall response rate in frontline recurrent/metastatic head & neck cancer — clinical upside that could boost future drug sales if confirmed. RYBREVANT FASPRO clinical results PR
• Positive Sentiment: Dividend/return focus highlighted in recent roundups — J&J remains a reliable dividend payer (recent quarterly payout noted), supporting income investor demand. Dividend Roundup: Halliburton, AbbVie, Johnson & Johnson, Delta Air Lines, and more
• Neutral Sentiment: Options and analyst attention have increased — can amplify near‑term moves but are not fundamental drivers by themselves. Monitor for large directional trades or fresh analyst revisions. Behind the Scenes of Johnson & Johnson’s Latest Options Trends
• Neutral Sentiment: Street coverage (Zacks, TipRanks) is keeping JNJ in focus — useful for sentiment but incremental to fundamental changes. Johnson & Johnson (JNJ) Is a Trending Stock
• Negative Sentiment: Insider selling: recent filings show EVP sales totaling millions of dollars (several thousand shares at ~$243–$244), which can be read negatively by some investors even if sales have benign explanations. Johnson & Johnson EVP Vanessa Broadhurst Sells 6,197 Shares
• Negative Sentiment: Ongoing talc litigation and renewed media focus on verdict risk continue to cloud valuation — legal overhang can limit multiple expansion and keeps headline risk elevated. Johnson & Johnson Balances Oncology Breakthrough With Rising Talc Litigation Risk

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.